Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Enovis Corporation is a global medical technology company focused on developing and delivering clinically differentiated solutions that improve patient outcomes and restore motion. The company operates primarily within the orthopedic and musculoskeletal healthcare industries, serving healthcare professionals and patients through both non-surgical and surgical treatment solutions. Enovis generates revenue through the design, manufacture, and distribution of medical devices, with a focus on evidence-based innovation and strong clinical support.
The company’s core business lines include Prevention & Recovery products such as orthopedic braces, compression therapy, and rehabilitation technologies, as well as Reconstructive solutions focused on joint replacement implants. Enovis serves hospitals, ambulatory surgery centers, orthopedic surgeons, physical therapists, and patients, with a strategic emphasis on clinically differentiated products and physician partnerships. The company traces its current form to its 2022 spin-off from Colfax Corporation, following Colfax’s acquisition of DJO Global in 2019, which established the foundation of Enovis’s musculoskeletal platform.
Business Operations
Enovis operates through two primary business segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment, anchored by the DJO brand, includes bracing and supports, foot and ankle solutions, compression therapy, and rehabilitation technologies, generating revenue through product sales to hospitals, clinics, and distributors. The Reconstructive segment focuses on orthopedic implants for hip, knee, and shoulder replacement, primarily serving orthopedic surgeons and surgical facilities.
The company maintains a vertically integrated model encompassing product development, manufacturing, and global distribution. Operations span both domestic and international markets, with manufacturing and R&D capabilities in North America and Europe. Enovis also leverages surgeon education programs, clinical data, and digital tools to support adoption of its technologies. Its portfolio includes wholly owned subsidiaries such as DJO, LimaCorporate, and other regional operating entities that support localized market strategies.
Strategic Position & Investments
Enovis’s strategic direction emphasizes accelerated growth in high-value orthopedic markets through innovation, disciplined capital deployment, and portfolio expansion. A cornerstone of this strategy was the acquisition of LimaCorporate in 2023, which significantly expanded Enovis’s Reconstructive segment and strengthened its presence in advanced joint replacement technologies, including 3D-printed implants and patient-specific solutions.
The company continues to invest in emerging technologies such as digital surgery tools, data-driven rehabilitation platforms, and additive manufacturing for orthopedic implants. Enovis positions itself as a challenger brand in orthopedics, focusing on speed to market, close collaboration with clinicians, and targeted investment rather than broad-based scale. Strategic priorities consistently highlight organic innovation complemented by selective acquisitions in adjacent musculoskeletal categories.
Geographic Footprint
Enovis is headquartered in the United States and maintains a broad international footprint across North America, Europe, Asia-Pacific, and select emerging markets. The company derives a significant portion of its revenue from the U.S. market, while Europe represents a growing strategic region, particularly following the integration of LimaCorporate, which has a strong base in Italy and broader European distribution.
International operations include manufacturing, R&D, and commercial organizations tailored to regional regulatory and clinical requirements. Enovis’s global footprint supports both mature orthopedic markets and faster-growing international healthcare systems, enabling diversified revenue streams and reduced dependence on any single geography.
Leadership & Governance
Enovis is led by an executive team with extensive experience in medical technology, orthopedics, and global operations. Leadership emphasizes a performance-driven culture centered on continuous improvement, customer focus, and innovation aimed at improving patient outcomes. The governance structure aligns executive compensation and strategic decision-making with long-term shareholder value creation.
Key members of the leadership team include:
- Matthew Trerotola – Chief Executive Officer
- Brady A. Shirley – Chief Financial Officer
- Dave Smith – President, Reconstructive
- Brady Shirley – President, Prevention & Recovery
- Eric Major – Chief Legal Officer and Corporate Secretary
The leadership team’s strategic vision focuses on building a differentiated global orthopedic company through operational excellence, targeted investment, and disciplined growth execution.